Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
Malinda West, MD, MS, discusses the use of adjuvant endocrine therapy in combination with CDK4/6 inhibitors in the treatment of patients with early-stage HER2-negative breast cancer.
Dr Vinod Ravi talks about nab-SIROLIMUS and reviews the data from the AMPECT trial.
Sometimes, clinicians do not acknowledge how patients' values and beliefs influence how they ascribe meaning to their illness, how they prefer to receive information, and how they make decisions until the end-of-life stage, leading to misunderstandings between clinicians and patients.
Jakub Svoboda, MD, discusses the implications of the phase 3 SWOG 1826 trial of nivolumab plus doxorubicin, vinblastine, and dacarbazine in patients with advanced classical Hodgkin lymphoma.
Adjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.
Accelerating progress in childhood cancer faces three main obstacles: funding, drugs, and family support.
John Koreth, MBBS, DPhil, discusses the key objectives of the phase 3 EQUATOR trial in acute graft-versus-host disease.
Heather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.
Wasif M. Saif, MD, MBBS, discusses recommendations for germline testing in patients with pancreatic cancer.
As improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.
Linda Hasunuma, PhD, highlights the importance of empathy and support as it relates to mentorship, as well as advice for establishing a successful fellowship program and communication strategies.
Collin Blakely, MD, PhD, discusses a phase 2 trial evaluating the use of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutated non-small cell lung cancer, findings from which were presented at the 2023 ASCO Annual Meeting.
Timothy M. Schmidt, MD, discusses the promise of bispecific antibodies in patients with multiple myeloma.
Julia S. Wong, MD, discusses findings from data presented on patient-reported toxicity results from the randomized trial of fractionation following breast reconstruction in patients with breast cancer.
Amanda L. Jackson, MD, discusses choosing between VEGF inhibitors and PARP inhibitors in the treatment of patients with recurrent platinum-sensitive ovarian cancer.
Alexandra Stefanovic, MD, discusses the emergence of umbralisib in marginal zone lymphoma and follicular lymphoma.
Jue Wang, MD, discusses how to approach testing for molecular alterations in patients with relapsed or refractory urothelial carcinoma.
Ricardo D. Parrondo, MD, discusses the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.
Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.
Tiffany S. Lai, MD, discusses the role of maintenance therapy and secondary cytoreduction in ovarian cancer.
Insurance companies are beginning to indirectly manage prescribing to better manage costs.
Expert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer.
Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non–small cell lung cancers to respond to an immune checkpoint blockade, a therapy that harnesses the immune system to fight malignant tumors.
Danny Nguyen, MD, discusses management strategies for mobocertinib-related gastrointestinal toxicities in EGFR exon 20 insertion–positive non–small cell lung cancer.
Shahrzad A. Zamani, discusses the prevalence of cancer disparities in patients with cancer in sexual and gender minority populations.
A marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.
Closing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.
Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.